These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 15685830)

  • 1. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.
    Ilson DH
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):22-5. PubMed ID: 15685830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
    Ilson DH; Saltz L; Enzinger P; Huang Y; Kornblith A; Gollub M; O'Reilly E; Schwartz G; DeGroff J; Gonzalez G; Kelsen DP
    J Clin Oncol; 1999 Oct; 17(10):3270-5. PubMed ID: 10506629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irinotecan in esophageal cancer.
    Ilson DH; Minsky B
    Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):32-6. PubMed ID: 14569846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan, cisplatin, and radiation in esophageal cancer.
    Ilson DH; Minsky B; Kelsen D
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):11-5. PubMed ID: 12109799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
    Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
    J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus.
    Lee DH; Kim HT; Han JY; Lee SY; Yoon SJ; Kim HY; Lee JS
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):83-8. PubMed ID: 17468871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer.
    Ilson DH; Bains M; Kelsen DP; O'Reilly E; Karpeh M; Coit D; Rusch V; Gonen M; Wilson K; Minsky BD
    J Clin Oncol; 2003 Aug; 21(15):2926-32. PubMed ID: 12885811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer.
    Knox JJ; Wong R; Visbal AL; Horgan AM; Guindi M; Hornby J; Xu W; Ringash J; Keshavjee S; Chen E; Haider M; Darling G
    Cancer; 2010 Sep; 116(17):4023-32. PubMed ID: 20533506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma.
    Ajani JA; Baker J; Pisters PW; Ho L; Mansfield PF; Feig BW; Charnsangavej C
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):16-8. PubMed ID: 12109800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.
    Rivera F; Galán M; Tabernero J; Cervantes A; Vega-Villegas ME; Gallego J; Laquente B; Rodríguez E; Carrato A; Escudero P; Massutí B; Alonso-Orduña V; Cardenal A; Sáenz A; Giralt J; Yuste AL; Antón A; Aranda E;
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1430-6. PubMed ID: 19540072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
    Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
    Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer.
    Burkart C; Bokemeyer C; Klump B; Pereira P; Teichmann R; Hartmann JT
    Anticancer Res; 2007; 27(4C):2845-8. PubMed ID: 17695458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II clinical trial with 5-fluorouracil, recombinant interferon-alpha-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus.
    Wadler S; Haynes H; Beitler JJ; Hu X; Fell S; Camacho M; Levine B; Wiernik PH
    Cancer; 1996 Jul; 78(1):30-4. PubMed ID: 8646722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study.
    Pozzo C; Barone C; Szanto J; Padi E; Peschel C; Bükki J; Gorbunova V; Valvere V; Zaluski J; Biakhov M; Zuber E; Jacques C; Bugat R
    Ann Oncol; 2004 Dec; 15(12):1773-81. PubMed ID: 15550582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancer.
    Watkins JM; Zauls AJ; Kearney PL; Shirai K; Ruppert BN; Harper JL; Sherman CA; Aguero EG; Reed CE; Sharma AK
    Jpn J Clin Oncol; 2011 Mar; 41(3):334-42. PubMed ID: 21084436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma.
    Enzinger PC; Kulke MH; Clark JW; Ryan DP; Kim H; Earle CC; Vincitore MM; Michelini AL; Mayer RJ; Fuchs CS
    Dig Dis Sci; 2005 Dec; 50(12):2218-23. PubMed ID: 16416165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer.
    Jeung HC; Rha SY; Noh SH; Roh JK; Chung HC
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):313-20. PubMed ID: 16770582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus.
    Ilson DH; Forastiere A; Arquette M; Costa F; Heelan R; Huang Y; Kelsen DP
    Cancer J; 2000; 6(5):316-23. PubMed ID: 11079171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
    Loupakis F; Masi G; Fornaro L; Vasile E; Allegrini G; Fontana E; Granetto C; Salvatore L; Mentuccia L; Andreuccetti M; Cortesi E; Merlano M; Cascinu S; Falcone A
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):559-66. PubMed ID: 20237927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.